重组人内皮抑制素抑制肺黑色素瘤转移  

RhEndostatin inhibits the growth of pulmonary metastases

作　　者：张海宁[1] 宋海峰[2] 张晋昕[3] 汤仲明[2] 郝一彬[4] 

机构地区：[1]广州医学院药理学教研室,510182 [2]军事医学科学院,北京市100850 [3]中山大学公共卫生学院,广州市510080 [4]山西医科大学药理学教研室,太原市030001

出　　处：《实用医学杂志》2008年第16期2766-2768,共3页The Journal of Practical Medicine

摘　　要：目的:研究重组人内皮抑制素的抗肿瘤活性。方法:鸡胚绒毛尿囊膜实验观察重组人内皮抑制素的体内抗血管生成活性;将B16-BL6黑色素瘤细胞尾静脉注入C57BL/6小鼠体内,构建肺转移瘤模型,评价重组人内皮抑制素的抗肿瘤活性。结果:重组人内皮抑制素可以明显抑制血管的生成。与生理盐水组相比,高、中、低剂量重组人内皮抑制素明显减少肺转移瘤数目,并对由于黑色素瘤体积的增长而引起的肺重增加也有抑制趋势。结论:重组人内皮抑制素通过抑制血管生成可以抑制肺黑色素瘤的转移。Objective To evaluate the anti-tumor efficacy of rhEndostatin. Methods The chick chorioallantoic membrane （CAM） assay was used to test the ability of rhEndostatin to inhibit in vivo angiogenesis. The B16-BL6 experimental pulmonary metastases model was prepared by injecting the cell suspension via the lateral tail vein of C57BL/6 mouse. Results The results showed that rhEndostatin caused inhibitory effects on the angiogenesis in the tested CAMs at the dosage of 100 or 20 μg/egg. The significant reduction in the number of pulmonary tumors was observed following treatment of mice with different doses of rhEndostatin. The lung weights of mice treated with rhEndostatin were also inhibited as compared with the group injected with physiological saline. Conclusion The results suggest that systemic therapy with rhEndostatin causes a potential suppression of angiogenesis, which may result in a strong restraint to growth and metastases of tumor.

关 键 词：黑色素瘤 抑制素类 鸡胚绒毛尿囊膜生物鉴定法 

分 类 号：R734.2[医药卫生—肿瘤]